Tetrahydrocannabivarin (THCV) is a propyl analogue of THC. THCV is usually low in concentration in dried plant material. However, weights up to as high as 16% THCV by dry weight have been recorded.
(Meijer & Hammond, 2005).
THCV can behave as both an agonist and an antagonist at CB1 receptors depending on the concentration
(
Pertwee, 2008).
THCV produces weight loss. In tests in obese mice (Ratatouille gone wrong), THCV decreased body fat and serum leptin concentrations, with increased energy expenditure.
(
Riedel et al.2009).
THCV has demonstrated prominent anticonvulsant properties in rodent cerebellum and pyriform cortex
(
Hill et al., 2013).
Tetrahydrocannabivarin (THCV) on Parkinson's Disease:
Acute administration of THCV attenuated the motor inhibition caused by 6-hydroxydopamine mice.
(
Garcia et al 2011)
THCV has therapeutic potential for ameliorating some of the negative, cognitive and positive symptoms of schizophrenia.
(
Cascio et al 2015)
Special thanks to Dr. Ethan Russo and Jahan Marcu PhD for their publishing:
Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads. Which collated much of the information here.